FDA Grants Regular Approval to Blinatumomab and Expands Indication to Include Philadelphia Chromosome-Positive B Cell ALL
U.S. Food and Drug Administration
Voice
Description
On July 11, 2017, the U.S. Food and Drug Administration approved blinatumomab (Blincyto®, Amgen Inc.) for the treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL) in adults and children.
ONS Articles
Dive into a rich source of oncology nursing expertise with ONS articles.
View All Articles